Glioblastoma Multiforme Key Companies

View All

Glioblastoma-Multiforme-Market-Analysis-and-Pipeline-Insights
Glioblastoma Multiforme Market: Emerging Pipeline Therapies To Keep A Keen Eye On

The present Glioblastoma multiforme (GBM) market has several unmet needs. Poor prognosis, 10-15 months median survival rate, no curative treatment to the patients, limited treatment options, drug resistance, incapability of therapies to cross BBB (blood-brain-barrier), intratumor heterogeneity, and a high mortality...

Find More